



Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™

January 28, 2026

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan. 28, 2026-- [Spruce Biosciences, Inc.](#) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data on the long-term administration of its tralesenidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo syndrome type B (MPS IIIB) will be presented at the [22nd Annual WORLDSymposium™](#) taking place February 2-6, 2026 in San Diego. A second presentation will detail divergent outcomes in two male siblings, one of whom was treated with TA-ERT in a clinical trial while the other received care without treatment.

WORLDSymposium 2026 Presentation Details

Title: Long-term administration of tralesenidase alfa enzyme replacement therapy (TA-ERT) results in profound and durable reduction of heparan sulfate (HS) and stabilization of cognitive function and cortical gray matter volume (CGMV) in patients with Sanfilippo syndrome type B (MPS IIIB)

Platform Presentation Date & Time: 1:42 – 1:54 p.m. PT on February 5, 2026

Location: Harbor Ballroom

Presenter: Nicole Muschol, M.D., International Center for Lysosomal Disorders (ICLD) at the University Medical Center Hamburg-Eppendorf in Germany

Authors: Nicole Muschol, M.D.; Mona Lindschau, M.D.; Ilyas Okur, M.D.; Fatih Ezgu, M.D.; Maria J. de Castro Lopez, M.D.; Spyros Batziros, M.D.; Igor Nestrasil, M.D.; Saba Sile, M.D.; Ting Chang, Ph.D.; Jeffrey Zhang, Ph.D.; Javier Szwarcberg, M.D., M.P.H.; Paul Harmatz, M.D.

These data will also be presented as poster #259 on February 5 from 3:30 – 5:30 p.m. PT at Kiosk 30-B

Title: Divergent neurocognitive outcomes in mucopolysaccharidosis (MPS) type IIIB siblings: Tralesenidase alfa versus supportive management (poster #64)

Poster Presentation Date & Time: 3:30 – 5:30 p.m. PT on February 5, 2026

Location: Kiosk 8-C

Presenter: Irene J. Chang, M.D., Assistant Professor at the University of California, San Francisco

Authors: Irene J. Chang, M.D.; Jacqueline Madden, P.N.P.; Erin Jozwiak, N.P.; Saba Sile, M.D.; Ting Chang, Ph.D.; Javier Szwarcberg, M.D., M.P.H.; Paul Harmatz, M.D.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. To learn more, visit www.sprucebio.com and follow us on [X](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260128573673/en/): <https://www.businesswire.com/news/home/20260128573673/en/>

Media

Carolyn Hawley

Inizio Evoke Comms

Carolyn.Hawley@inizioevoke.com

media@sprucebio.com

Investors

Samir Gharib

President and CFO

Spruce Biosciences, Inc.

investors@sprucebio.com

Source: Spruce Biosciences, Inc.